186 related articles for article (PubMed ID: 16643994)
1. Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group.
Brewer CA; Blessing JA; Nagourney RA; Morgan M; Hanjani P
Gynecol Oncol; 2006 Nov; 103(2):446-50. PubMed ID: 16643994
[TBL] [Abstract][Full Text] [Related]
2. A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
Covens A; Blessing J; Bender D; Mannel R; Morgan M;
Gynecol Oncol; 2006 Mar; 100(3):586-90. PubMed ID: 16249022
[TBL] [Abstract][Full Text] [Related]
3. Treatment of recurrent platinum resistant ovarian or peritoneal cancer with gemcitabine and doxorubicin: A phase I/II trial of the Puget Sound Oncology Consortium (PSOC 1602).
Goff BA; Thompson T; Greer BE; Jacobs A; Storer B;
Am J Obstet Gynecol; 2003 Jun; 188(6):1556-62; discussion 1562-4. PubMed ID: 12824993
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma.
Rose PG; Mossbruger K; Fusco N; Smrekar M; Eaton S; Rodriguez M
Gynecol Oncol; 2003 Jan; 88(1):17-21. PubMed ID: 12504621
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant recurrent ovarian and primary peritoneal cancer by the Korean Cancer Study Group (KCSG)_KCSG GY10-10.
Hong SH; Lee S; Kim HG; Lee HJ; Jung KH; Lee SC; Lee NR; Yun J; Woo IS; Park KH; Kim KH; Kim HY; Rha SY; Byun JH
Gynecol Oncol; 2015 Feb; 136(2):212-7. PubMed ID: 25462205
[TBL] [Abstract][Full Text] [Related]
6. Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan: a phase II trial of the Puget Sound Oncology Consortium.
Goff BA; Holmberg LA; Veljovich D; Kurland BF;
Gynecol Oncol; 2008 Aug; 110(2):146-51. PubMed ID: 18538834
[TBL] [Abstract][Full Text] [Related]
7. Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma.
Bozas G; Bamias A; Koutsoukou V; Efstathiou E; Gika D; Papadimitriou CA; Dimopoulos MA
Gynecol Oncol; 2007 Mar; 104(3):580-5. PubMed ID: 17052747
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma.
Tewari D; Monk BJ; Hunter M; Falkner CA; Burger RA
Invest New Drugs; 2004 Nov; 22(4):475-80. PubMed ID: 15292718
[TBL] [Abstract][Full Text] [Related]
9. Triplet combination of gemcitabine, carboplatin, and paclitaxel in previously treated, relapsed ovarian and peritoneal carcinoma: an experience in Taiwan.
Liu FS; Ho ES; Hung MJ; Hwang SF; Lu CH; Ke YM
Gynecol Oncol; 2004 Aug; 94(2):393-7. PubMed ID: 15297178
[TBL] [Abstract][Full Text] [Related]
10. A phase I trial of gemcitabine and topotecan in previously treated ovarian or peritoneal cancer: a Gynecologic Oncology Group study.
Chen MD; Fleming GF; Mitchell S; Horowitz I
Gynecol Oncol; 2006 Jan; 100(1):111-5. PubMed ID: 16150481
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: an Australian and New Zealand Gynaecological Oncology Group study.
Harnett P; Buck M; Beale P; Goldrick A; Allan S; Fitzharris B; De Souza P; Links M; Kalimi G; Davies T; Stuart-Harris R
Int J Gynecol Cancer; 2007; 17(2):359-66. PubMed ID: 17362313
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer.
Walsh CS; Kamrava M; Rogatko A; Kim S; Li A; Cass I; Karlan B; Rimel BJ
PLoS One; 2021; 16(6):e0252665. PubMed ID: 34081738
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy.
Sehouli J; Stengel D; Oskay G; Camara O; Hindenburg HJ; Klare P; Blohmer J; Heinrich G; Elling D; Ledwon P; Lichtenegger W;
Ann Oncol; 2002 Nov; 13(11):1749-55. PubMed ID: 12419747
[TBL] [Abstract][Full Text] [Related]
14. Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II Trial.
Sabbatini P; Aghajanian C; Leitao M; Venkatraman E; Anderson S; Dupont J; Dizon D; O'Flaherty C; Bloss J; Chi D; Spriggs D
Clin Cancer Res; 2004 May; 10(9):2962-7. PubMed ID: 15131031
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
Brewer CA; Blessing JA; Nagourney RA; McMeekin DS; Lele S; Zweizig SL
Gynecol Oncol; 2006 Feb; 100(2):385-8. PubMed ID: 16271750
[TBL] [Abstract][Full Text] [Related]
16. Feasibility of intravenous gemcitabine and an intraperitoneal platinum agent in the treatment of ovarian cancer.
Giuntoli RL; Bristow RE; Diaz-Montes TP; Armstrong DK
J Chemother; 2011 Jun; 23(3):163-7. PubMed ID: 21742586
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine and pegylated liposomal doxorubicin alternating with cisplatin plus cyclophosphamide in platinum refractory/resistant, paclitaxel-pretreated, ovarian carcinoma.
Pectasides D; Xiros N; Papaxoinis G; Aravantinos G; Sykiotis C; Pectasides E; Psyrri A; Koumarianou A; Gaglia A; Gouveris P; Economopoulos T
Gynecol Oncol; 2008 Jan; 108(1):47-52. PubMed ID: 17915300
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients.
Nagourney RA; Brewer CA; Radecki S; Kidder WA; Sommers BL; Evans SS; Minor DR; DiSaia PJ
Gynecol Oncol; 2003 Jan; 88(1):35-9. PubMed ID: 12504624
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of gemcitabine plus cisplatin in previously untreated advanced ovarian cancer.
Gallardo D; Calderillo G; Serrano A; Alexander F; Rodríguez G; Pérez L; de la Garza J; Orate-Ocaña L; Otero J
Anticancer Res; 2006; 26(4B):3137-41. PubMed ID: 16886647
[TBL] [Abstract][Full Text] [Related]
20. The safety and efficacy of cisplatin plus gemcitabine in recurrent ovarian cancer.
Tomita Y; Saito T; Okadome M; Eto T; Ariyoshi K; Shimamoto K
Int J Clin Oncol; 2014 Aug; 19(4):662-6. PubMed ID: 23887730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
